1-20 of 78
axicabtagene ciloleucel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Free
Clinical Trials & Observations Brief Report
Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, Richard E. Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (12): 1081–1085.
https://doi.org/10.1182/blood.2021010930
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Free
Clinical Trials & Observations
Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, John Tamaresis, Loretta J. Nastoupil, Miriam T. Jacobs, Armin Ghobadi, Yi Lin, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Andre Goy, Khoan Vu, Charalambos Andreadis, Javier Munoz, N. Nora Bennani, Julie M. Vose, Kathleen A. Dorritie, Sattva S. Neelapu, Frederick L. Locke, Aaron P. Rapoport, Brian T. Hill, David B. Miklos
Journal: Blood
Blood (2021) 137 (13): 1832–1835.
https://doi.org/10.1182/blood.2020006245
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Free
Clinical Trials & Observations
Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke
Journal: Blood
Blood (2020) 135 (23): 2106–2109.
https://doi.org/10.1182/blood.2019004162
Published: 2020
Includes: Supplemental data
Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Free
Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2199.
https://doi.org/10.1182/blood-2019-131533
Published: 2019
Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Free
Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4719.
https://doi.org/10.1182/blood-2019-122587
Published: 2019
Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Free
Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 764.
https://doi.org/10.1182/blood-2019-124750
Published: 2019
Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Free
Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 793.
https://doi.org/10.1182/blood-2019-124364
Published: 2019
Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

Free
N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD MSc, Michael D. Jain, MD PhD, Julio C. Chavez, MD, Amanda F Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Khoan Vu, MD, Charalambos Andreadis, MD, Javier Munoz, MD MS, FACP, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Frederick L. Locke, MD, Sattva S Neelapu, MD, Yi Lin, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 763.
https://doi.org/10.1182/blood-2019-129097
Published: 2019
Journal Articles

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Free
Paolo Strati, MD, Sudhakar Tummala, Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Swaminathan P. Iyer, MD, Ranjit Nair, MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael L. Wang, MD, Chelsea Camille Pinnix, MD PhD, Sherry Adkins, ANP, Catherine M. Claussen, MS, Charles Martinez, Misha Hawkins, Nicole Johnson, Shirley George, Sattva S Neelapu, MD, Linda Chi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 765.
https://doi.org/10.1182/blood-2019-125769
Published: 2019
Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Free
Andrea Kuhnl, Claire Roddie, PhD MD, Nuria Martinez-Cibrian, Tobias F Menne, MD PhD FRCPath, Kim Linton, MBChB PhD, Sanne Lugthart, Sridhar Chaganti, MDPhDMRCP,FRCPath, Robin Sanderson, MRCP,FRCPath, Maria A V Marzolini, Jane Norman, MD, Wendy Osborne, MD, John Radford, Stephen Robinson, MBBS, PhD BSc, Ram Malladi, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Maeve A O'Reilly, MBBCHBAO, Muhammad Saif, MD, Geoff Shenton, Adrian Bloor, FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David A. Irvine, BSc, MBBChir, MRCP, FRCPath, PhD, Orla Stewart, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Kristian M Bowles, MBBS, PhD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Rod Johnson, Andrew K McMillan, FRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 767.
https://doi.org/10.1182/blood-2019-124177
Published: 2019
Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Free
Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 884.
https://doi.org/10.1182/blood-2019-132057
Published: 2019
Journal Articles

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

Free
Adam S. Kittai, MD, Max J. Gordon, MD, Agrima Mian, MBBS, MD, Lindsey Fitzgerald, MD, Jennifer Bishop, Deborah M. Stephens, DO, Sarah J. Nagle, MD, Brian T. Hill, MD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 780.
https://doi.org/10.1182/blood-2019-124694
Published: 2019
Journal Articles

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Free
Zinaida Good, PhD, Jay Y. Spiegel, MDFRCPC, Bita Sahaf, PhD, Meena B. Malipatlolla, Matthew J. Frank, MD PhD, John Baird, MD, Lori S Muffly, MD, Gursharan K. Claire, MPH, Juliana Craig, BA, Katherine A. Kong, Sean Bendall, PhD, David B Miklos, MD PhD, Crystal L. Mackall, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 779.
https://doi.org/10.1182/blood-2019-130815
Published: 2019
Journal Articles

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Free
Miriam T. Jacobs, MD, Michael D. Jain, MD PhD, Jay Y. Spiegel, MDFRCPC, Loretta J. Nastoupil, MD MSc, Yibo Li, MD, Gao Feng, Matthew A. Lunning, DO, FACP, Lazaros J Lekakis, MD, Saurabh Dahiya, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Charalambos Andreadis, MD MSCE, Javier Munoz, MD, Julio Chavez, N. Nora Bennani, MD, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Sattva S Neelapu, MD, Armin Ghobadi, MD, Frederick L. Locke, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1583.
https://doi.org/10.1182/blood-2019-131168
Published: 2019
Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Free
Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1599.
https://doi.org/10.1182/blood-2019-127490
Published: 2019
Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Free
Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 550.
https://doi.org/10.1182/blood-2019-129015
Published: 2019
Journal Articles

Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion

Free
Jingmei Hsu, MD, Usama Gergis, MD MBA, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Danielle Guarneri, BS, CCRP, Maria Baldo, PA, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Robert Andrew Desimone, MD, Melissa M. Cushing, MD, Koen Van Besien, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1169.
https://doi.org/10.1182/blood-2019-131306
Published: 2019
Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Free
Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5238.
https://doi.org/10.1182/blood-2019-131941
Published: 2019
Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Free
Caspian Oliai, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5360.
https://doi.org/10.1182/blood-2019-129371
Published: 2019
Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Free
Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy
Journal: Blood
Blood (2019) 134 (Supplement_1): 5308.
https://doi.org/10.1182/blood-2019-128812
Published: 2019